Patients with bacterial infections successfully treated with RECCE® 327 (R327)Deadly bacterial pathogens treated with R327 include those identified by the.
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure 3 Clearing in a lawn of Escherichia coli (E. coli) on solid LB-agar media. Table 1 Table 1 RECCE® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) Category AIn an ex-vivo burn wound study, R327G showed a 4 to 5-log reduction (>99.99%) against Methicillin-re